In the field of targeted cancer therapy, NGR peptides have been extensively studied for their high specificity in recognizing tumor‐specific vascular ligands.[69, 70] In this study, NGR‐modified CAF‐derived exos demonstrated excellent tumor‐targeting ability, which is consistent with previous studies involving NGR. This evidence concerns the gene RTN4R and cancer.